Case Histories of Significant Advances: Tamoxifen, A Gold Standard Treatment for Breast Cancer

19 Pages Posted: 24 Aug 2020 Last revised: 1 Mar 2024

See all articles by Amar Bhide

Amar Bhide

Columbia University - Mailman School of Public Health

Srikant Datar

Harvard University - Accounting & Control Unit

Katherine Stebbins

Harvard University - Business School (HBS)

Date Written: May 15, 2021

Abstract

Our case history describes the development of tamoxifen, considered a “gold standard” treatment for millions of breast cancer patients. Specifically, we describe breast cancer treatments prior to tamoxifen’s development; the initial development of tamoxifen from 1960 to 1973; tamoxifen’s adoption as an adjuvant breast cancer treatment between 1973 and 1985; and the extension of tamoxifen’s use to include preventative treatment, between 1986 and 2002.

Suggested Citation

Bhide, Amar and Datar, Srikant and Stebbins, Katherine, Case Histories of Significant Medical Advances: Tamoxifen (May 15, 2021). Harvard Business School General Management Unit Working Paper No. 20-134, Harvard Business School Accounting & Management Unit Working Paper No. 20-134, Available at SSRN: https://ssrn.com/abstract=3679645 or http://dx.doi.org/10.2139/ssrn.3679645

Amar Bhide

Columbia University - Mailman School of Public Health ( email )

600 West 168th St., 6th Floor
New York, NY 10032
United States

Srikant Datar (Contact Author)

Harvard University - Accounting & Control Unit ( email )

Soldiers Field
Boston, MA 02163
United States
617-495-6543 (Phone)
617-496-7363 (Fax)

Katherine Stebbins

Harvard University - Business School (HBS) ( email )

Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
68
Abstract Views
920
PlumX Metrics